Table 4.
Association between treatment and survival after recurrence in the overall cohort and by MSI/MMR status
| Adjusted HRa) (95% CI) | p-value | |
|---|---|---|
| Overall | < 0.001 | |
| Adj–/CAR+ | 1 | |
| Adj+/CAR+ | 1.229 (0.947-1.596) | 0.121 |
| Adj–/CAR– | 2.820 (2.062-3.856) | < 0.001 |
| Adj+/CAR– | 3.583 (2.658-4.831) | < 0.001 |
| MSS/pMMR | < 0.001 | |
| Adj–/CAR+ | 1 | |
| Adj+/CAR+ | 1.133 (0.867-1.481) | 0.359 |
| Adj–/CAR– | 2.798 (2.012-3.890) | < 0.001 |
| Adj+/CAR– | 3.356 (2.464-4.570) | < 0.001 |
| MSI-H/dMMR | < 0.001 | |
| Adj–/CAR+ | 1 | |
| Adj+/CAR+ | 5.360 (1.472-19.517) | 0.011 |
| Adj–/CAR– | 4.491 (1.412-14.290) | 0.011 |
MSI, microsatellite instability; MMR, mismatch repair; HR, hazard ratio; CI, confidence interval; Adj, adjuvant chemotherapy; CAR, chemotherapy after recurrence; MSS, microsatellite stable; pMMR, proficient mismatch repair; MSI-H, microsatellite instability high; dMMR, deficient mismatch repair.
a)
Adjusted by age, sex, and institution.